Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma

Daichi Maeda, Xu Chen, Bin Guan, Shunsuke Nakagawa, Tetsu Yano, Yuji Taketani, Masashi Fukayama, Tian-Li Wang, Ie Ming Shih

Research output: Contribution to journalArticle

Abstract

Ovarian clear cell carcinoma (CCC) is a unique type of ovarian cancer characterized by distinct clinicopathological and molecular features. CCC is considered to be a highly malignant disease because it is resistant to conventional chemotherapy, and when presented at advanced stages, it has a dismal overall survival. Identifying and characterizing biomarkers associated with its malignant behavior is fundamental toward elucidating the mechanisms underlying its aggressive phenotype. In this study, we performed immunohistochemical analysis on 89 CCCs to assess their expression of Rsf-1 (HBXAP), a chromatin-remodeling gene frequently amplified and overexpressed in several types of human cancer. We found that 73 (82%) of the 89 CCCs expressed Rsf-1 and most importantly, there was a statistically significant correlation between Rsf-1 immunostaining intensity and the 2 disease parameters: advanced stage (P=0.008) and status of retroperitoneal lymph node metastasis (P=0.023). However, there was no correlation between Rsf-1 expression and patient age, peritoneal tumor dissemination, or overall survival. In conclusion, a higher expression level of Rsf-1 is associated with advanced clinical stage and lymph node metastasis in CCC. Our data suggest that Rsf-1 participates in tumor progression in CCC, and indicates that the contribution of Rsf-1 to disease aggressiveness deserves further study.

Original languageEnglish (US)
Pages (from-to)30-35
Number of pages6
JournalInternational Journal of Gynecological Pathology
Volume30
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Lymph Nodes
Neoplasm Metastasis
Carcinoma
Neoplasms
Chromatin Assembly and Disassembly
Survival
Ovarian Neoplasms
Biomarkers
Phenotype
Drug Therapy
Genes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Obstetrics and Gynecology

Cite this

Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma. / Maeda, Daichi; Chen, Xu; Guan, Bin; Nakagawa, Shunsuke; Yano, Tetsu; Taketani, Yuji; Fukayama, Masashi; Wang, Tian-Li; Shih, Ie Ming.

In: International Journal of Gynecological Pathology, Vol. 30, No. 1, 01.2011, p. 30-35.

Research output: Contribution to journalArticle

Maeda, Daichi ; Chen, Xu ; Guan, Bin ; Nakagawa, Shunsuke ; Yano, Tetsu ; Taketani, Yuji ; Fukayama, Masashi ; Wang, Tian-Li ; Shih, Ie Ming. / Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma. In: International Journal of Gynecological Pathology. 2011 ; Vol. 30, No. 1. pp. 30-35.
@article{65502eee58ca487485a80ed5ee93f978,
title = "Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma",
abstract = "Ovarian clear cell carcinoma (CCC) is a unique type of ovarian cancer characterized by distinct clinicopathological and molecular features. CCC is considered to be a highly malignant disease because it is resistant to conventional chemotherapy, and when presented at advanced stages, it has a dismal overall survival. Identifying and characterizing biomarkers associated with its malignant behavior is fundamental toward elucidating the mechanisms underlying its aggressive phenotype. In this study, we performed immunohistochemical analysis on 89 CCCs to assess their expression of Rsf-1 (HBXAP), a chromatin-remodeling gene frequently amplified and overexpressed in several types of human cancer. We found that 73 (82{\%}) of the 89 CCCs expressed Rsf-1 and most importantly, there was a statistically significant correlation between Rsf-1 immunostaining intensity and the 2 disease parameters: advanced stage (P=0.008) and status of retroperitoneal lymph node metastasis (P=0.023). However, there was no correlation between Rsf-1 expression and patient age, peritoneal tumor dissemination, or overall survival. In conclusion, a higher expression level of Rsf-1 is associated with advanced clinical stage and lymph node metastasis in CCC. Our data suggest that Rsf-1 participates in tumor progression in CCC, and indicates that the contribution of Rsf-1 to disease aggressiveness deserves further study.",
author = "Daichi Maeda and Xu Chen and Bin Guan and Shunsuke Nakagawa and Tetsu Yano and Yuji Taketani and Masashi Fukayama and Tian-Li Wang and Shih, {Ie Ming}",
year = "2011",
month = "1",
doi = "10.1097/PGP.0b013e3181e9a319",
language = "English (US)",
volume = "30",
pages = "30--35",
journal = "International Journal of Gynecological Pathology",
issn = "0277-1691",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma

AU - Maeda, Daichi

AU - Chen, Xu

AU - Guan, Bin

AU - Nakagawa, Shunsuke

AU - Yano, Tetsu

AU - Taketani, Yuji

AU - Fukayama, Masashi

AU - Wang, Tian-Li

AU - Shih, Ie Ming

PY - 2011/1

Y1 - 2011/1

N2 - Ovarian clear cell carcinoma (CCC) is a unique type of ovarian cancer characterized by distinct clinicopathological and molecular features. CCC is considered to be a highly malignant disease because it is resistant to conventional chemotherapy, and when presented at advanced stages, it has a dismal overall survival. Identifying and characterizing biomarkers associated with its malignant behavior is fundamental toward elucidating the mechanisms underlying its aggressive phenotype. In this study, we performed immunohistochemical analysis on 89 CCCs to assess their expression of Rsf-1 (HBXAP), a chromatin-remodeling gene frequently amplified and overexpressed in several types of human cancer. We found that 73 (82%) of the 89 CCCs expressed Rsf-1 and most importantly, there was a statistically significant correlation between Rsf-1 immunostaining intensity and the 2 disease parameters: advanced stage (P=0.008) and status of retroperitoneal lymph node metastasis (P=0.023). However, there was no correlation between Rsf-1 expression and patient age, peritoneal tumor dissemination, or overall survival. In conclusion, a higher expression level of Rsf-1 is associated with advanced clinical stage and lymph node metastasis in CCC. Our data suggest that Rsf-1 participates in tumor progression in CCC, and indicates that the contribution of Rsf-1 to disease aggressiveness deserves further study.

AB - Ovarian clear cell carcinoma (CCC) is a unique type of ovarian cancer characterized by distinct clinicopathological and molecular features. CCC is considered to be a highly malignant disease because it is resistant to conventional chemotherapy, and when presented at advanced stages, it has a dismal overall survival. Identifying and characterizing biomarkers associated with its malignant behavior is fundamental toward elucidating the mechanisms underlying its aggressive phenotype. In this study, we performed immunohistochemical analysis on 89 CCCs to assess their expression of Rsf-1 (HBXAP), a chromatin-remodeling gene frequently amplified and overexpressed in several types of human cancer. We found that 73 (82%) of the 89 CCCs expressed Rsf-1 and most importantly, there was a statistically significant correlation between Rsf-1 immunostaining intensity and the 2 disease parameters: advanced stage (P=0.008) and status of retroperitoneal lymph node metastasis (P=0.023). However, there was no correlation between Rsf-1 expression and patient age, peritoneal tumor dissemination, or overall survival. In conclusion, a higher expression level of Rsf-1 is associated with advanced clinical stage and lymph node metastasis in CCC. Our data suggest that Rsf-1 participates in tumor progression in CCC, and indicates that the contribution of Rsf-1 to disease aggressiveness deserves further study.

UR - http://www.scopus.com/inward/record.url?scp=78650935385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650935385&partnerID=8YFLogxK

U2 - 10.1097/PGP.0b013e3181e9a319

DO - 10.1097/PGP.0b013e3181e9a319

M3 - Article

VL - 30

SP - 30

EP - 35

JO - International Journal of Gynecological Pathology

JF - International Journal of Gynecological Pathology

SN - 0277-1691

IS - 1

ER -